This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571) Cancer Survivorship (258) Children and Young People With Cancer, Pediatric Oncology (59) Precision Medicine and Genetics (48) Cardiology (159)

Published on in Vol 11, No 2 (2022): February

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/27898, first published .
Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study

Authors of this article:

Oliver Zolk1 Author Orcid Image ;   Annika von dem Knesebeck2 Author Orcid Image ;   Norbert Graf3 Author Orcid Image ;   Thorsten Simon4 Author Orcid Image ;   Barbara Hero4 Author Orcid Image ;   Hashim Abdul-Khaliq5 Author Orcid Image ;   Mohamed Abd El Rahman5 Author Orcid Image ;   Claudia Spix6 Author Orcid Image ;   Benjamin Mayer7 Author Orcid Image ;   Susanne Elsner8 Author Orcid Image ;   Judith Gebauer9 Author Orcid Image ;   Thorsten Langer10 Author Orcid Image
Article Authors Cited by (4) Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.